Wird geladen...

Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression

Androgen receptor (AR) antagonism increases overall survival in prostate cancer; however, treatment failure leads to tumor progression and patient mortality. The effect of AR modulation on AR(+) non-tumor cells that participate in the resistance to AR antagonism is poorly understood. Tumor-infiltrat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunol Res
Hauptverfasser: Consiglio, Camila R., Udartseva, Olga, Ramsey, Kimberly D., Bush, Chioma, Gollnick, Sandra O.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484281/
https://ncbi.nlm.nih.gov/pubmed/32661092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0371
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!